专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022058023A1 KIT FOR COLLECTING SALIVA SAMPLES 审中-公开
公开(公告)号：WO2022058023A1
公开(公告)日：2022-03-24
申请号：PCT/EP2020/076183
申请日：2020-09-18
申请人： PROCOMCURE BIOTECH GMBH
发明人： WALLERSTORFER, Daniel , ÖNDER, Kamil
IPC分类号： A61B10/00 , C12Q1/6806 , C12Q1/70
摘要： The present invention refers to a receptable for body fluids wherein inside the receptable an coronavirus deactivating composition is present in solid form, use of said receptable for the collection of saliva, a kit for collecting saliva samples comprising said receptable, the use of said kit for collecting saliva, especially saliva comprising viral RNA and a method for the detection of RNA or DNA.

2. 发明申请

WO2016087616A1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS 审中-公开
标题翻译：基于咪唑的抗微生物剂
公开(公告)号：WO2016087616A1
公开(公告)日：2016-06-09
申请号：PCT/EP2015/078584
申请日：2015-12-03
申请人： PROCOMCURE BIOTECH GMBH
发明人： ÖNDER, Kamil , DATEMA, Roelf
IPC分类号： A61K31/4164 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4196 , A61K31/422 , A61K31/427 , A61P31/04 , A61P31/06 , A61P31/08 , A61P31/00 , A61K45/06 , A61K31/352
CPC分类号： A61K31/4178 , A61K31/352 , A61K31/4164 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/427 , A61K45/06 , A61K2300/00 , C07D403/04 , C07D405/04 , C07D409/04 , C07D417/04
摘要： The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.
摘要翻译：本发明涉及适用于治疗哺乳动物疾病的新型治疗剂，特别涉及适用于治疗哺乳动物微生物感染的新型治疗剂。本发明进一步涉及包含所述试剂的药物组合物在治疗哺乳动物的医学病症中的用途，特别是治疗微生物感染。本发明的药剂和药物组合物在治疗与抗生素抗性微生物有关的疾病中特别相关。

3. 发明申请

WO2016087618A1 IMIDAZOLE-BASED ANTIMICROBIAL AGENTS 审中-公开
标题翻译：基于咪唑的抗微生物剂
公开(公告)号：WO2016087618A1
公开(公告)日：2016-06-09
申请号：PCT/EP2015/078587
申请日：2015-12-03
申请人： PROCOMCURE BIOTECH GMBH
发明人： ÖNDER, Kamil , DATEMA, Roelf , MITCHELL, Dale , KONDRATOV, Ivan
IPC分类号： A61K31/4164 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4196 , A61K31/422 , A61K31/427 , A61P31/04 , A61P31/06 , A61P31/08 , A61P31/00 , A61K45/06 , A61K31/352
CPC分类号： A61K31/4178 , A61K31/352 , A61K31/4164 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/427 , A61K45/06 , A61K2300/00 , C07D403/04 , C07D405/04 , C07D409/04 , C07D417/04
摘要： The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.
摘要翻译：本发明涉及适用于治疗哺乳动物疾病的新型治疗剂，特别涉及适合用于治疗哺乳动物微生物感染的新型治疗剂。本发明还涉及包含所述药剂的药物组合物在哺乳动物治疗医学病症中的用途，特别是治疗微生物感染的用途。本发明的药剂和药物组合物在治疗与抗生素抗性微生物相关的疾病方面特别重要。

4. 发明申请

WO2009027495A1 METHOD FOR MANUFACTURING A MODIFIED PEPTIDE 审中-公开
标题翻译：制备改性肽的方法
公开(公告)号：WO2009027495A1
公开(公告)日：2009-03-05
申请号：PCT/EP2008/061362
申请日：2008-08-29
申请人： PROCOMCURE BIOTECH GMBH , ÖNDER, Kamil , BAUER, Johann W.
发明人： ÖNDER, Kamil , BAUER, Johann W.
IPC分类号： C12N15/10 , C07K14/31 , C07K14/47
CPC分类号： C12N15/1055 , C12N15/102
摘要： The present invention relates to a method for manufacturing a modified polypeptide from a first polypeptide, said modified polypeptide exhibiting altered binding properties to a target molecule and/or having a different amino acid sequence compared to a first polypeptide comprising the steps of a) providing a first cell comprising a nucleic acid molecule encoding for a first fusion polypeptide, said first fusion polypeptide comprising at least one first polypeptide and a transcriptional activation domain, and comprising optionally a nucleic acid mole cule encoding for a second fusion polypeptide, said second fusion polypeptide comprising the target mole cule or a polypeptide domain binding the target molecule and a DNA binding domain, whereby the cell further comprises a reporter gene encoding a reporter polypeptide operably linked to an upstream transcriptional regulatory sequence comprising a DNA binding site as target for the at least one first polypeptide or optionally a DNA binding site for the DNA binding domain of the second fusion polypeptide, b) cultivating the cells of step a), c) identifying at least one cell ex pressing the reporter polypeptide, d) isolating at least one nucleic acid molecule encoding for at least one first polypeptide of the at least one cell identified in step c), e) modifying the at least one nucleic acid molecule of step d) by introducing at least one mutation thus obtaining at least one modified nucleic acid molecule encoding for at least one modified polypeptide, f) introducing the at least one modified nucleic acid molecule of step e) into at least one second cell comprising optionally a nucleic acid molecule encoding for a second fusion polypeptide, said second fusion polypeptide comprising the target molecule or a polypeptide domain binding the target molecule and a DNA binding domain, and g) repeating steps a) to f) at least twice until a nucleic acid molecule encoding for a modified polypeptide is obtained and isolated in step d) exhibiting predetermined altered binding properties to the target molecule compared to the at least one first polypeptide and/or having a different amino acid sequence compared to the first polypeptide, wherein in the repeating steps a) to d) the first polypeptide is exchanged with the modified polypeptide of step e).
摘要翻译：本发明涉及一种从第一多肽制备修饰的多肽的方法，所述修饰的多肽与第一多肽相比显示改变的与靶分子的结合特性和/或具有与第一多肽相比具有不同氨基酸序列的方法，包括以下步骤：a）第一细胞，其包含编码第一融合多肽的核酸分子，所述第一融合多肽包含至少一个第一多肽和转录活化结构域，并且任选包含编码第二融合多肽的核酸分子，所述第二融合多肽包含所述靶分子或多肽结构域结合所述靶分子和DNA结合结构域，其中所述细胞还包含编码报告多肽的报告基因，所述报告多肽与上游转录调节序列可操作地连接，所述上游转录调控序列包含DNA结合位点作为所述至少一个第一多肽或任选的DNA结合蛋白 g）第二融合多肽的DNA结合结构域，b）培养步骤a）的细胞，c）鉴定至少一种按压所述报道多肽的细胞，d）分离至少一种编码至少一种的核酸分子在步骤c）中鉴定的至少一个细胞的第一多肽，e）通过引入至少一个突变来修饰步骤d）的至少一个核酸分子，从而获得编码至少一个修饰的多肽的至少一个修饰的核酸分子 f）将至少一个步骤e）的修饰的核酸分子导入到至少一个第二细胞中，任选地包含编码第二融合多肽的核酸分子，所述第二融合多肽包含靶分子或结合靶的多肽结构域分子和DNA结合结构域，以及g）重复步骤a）至f）至少两次，直至获得编码修饰多肽的核酸分子，并在步骤 d）与第一多肽相比，与至少一种第一多肽相比，表现出与靶分子预定的改变的结合特性，和/或与第一多肽相比具有不同的氨基酸序列，其中在重复步骤a）至d）中将第一多肽与步骤e）的修饰多肽。

5. 发明申请

WO2022171584A1 ASSAYS FOR THE DETECTION OF SARS-COV-2 MUTANTS 审中-公开
公开(公告)号：WO2022171584A1
公开(公告)日：2022-08-18
申请号：PCT/EP2022/052927
申请日：2022-02-08
申请人： PROCOMCURE BIOTECH GMBH
发明人： ÖNDER, Kamil , BREUNIG, Sven
IPC分类号： C12Q1/70
摘要： An oligonucleotide, having a 5' terminus and a 3' terminus, wherein said oligonucleotide is detectably labeled and has a nucleotide sequence that consists essentially of one of the nucleotide sequences selected from SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:60 and SEQID NO:77.

6. 发明申请

WO2016087615A1 NOVEL IMIDAZOLE-BASED HETEROCYCLIC COMPOUNDS 审中-公开
标题翻译：新型基于咪唑的杂环化合物
公开(公告)号：WO2016087615A1
公开(公告)日：2016-06-09
申请号：PCT/EP2015/078582
申请日：2015-12-03
申请人： PROCOMCURE BIOTECH GMBH
发明人： ÖNDER, Kamil , DATEMA, Roelf , MITCHELL, Dale , KONDRATOV, Ivan
IPC分类号： C07D403/04 , C07D405/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D495/04 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/427 , A61P31/04
CPC分类号： A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/427 , C07D403/04 , C07D405/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D495/04
摘要： The present invention relates to novel compounds of formula (I) suitable e.g. as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The present invention also relates to processes for making said agents.
摘要翻译：本发明涉及新的式（I）化合物，作为用于治疗哺乳动物疾病的治疗剂，特别是适合用于治疗哺乳动物微生物感染的新型治疗剂。本发明还涉及包含所述药剂的药物组合物在哺乳动物治疗医学病症中的用途，特别是治疗微生物感染的用途。本发明的药剂和药物组合物在治疗与抗生素抗性微生物相关的疾病方面特别重要。本发明还涉及制备所述试剂的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式